|

Sargramostim Clinical Trials

8 actively recruiting trials across 8 locations

-1 trial since June 2026

Also known as: 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, GM-CSF, Granulocyte Macrophage Colony Stimulating Factor, Leukine +5 more

Pipeline

Phase 2: 5Phase 3: 1Phase 1/2: 2

Top Sponsors

  • University of Washington1
  • University of Colorado, Denver1
  • Roswell Park Cancer Institute1
  • Northside Hospital, Inc.1
  • Nationwide Children's Hospital1

Indications

  • Cancer7
  • Metastatic Triple-Negative Breast Carcinoma2
  • Anatomic Stage IV Breast Cancer AJCC v82
  • Neuroblastoma2
  • Lung Cancer2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.